[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611294":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":60,"collaborators":28,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":28,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":46,"whyStopped":28,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"St. Petersburg State Pavlov Medical University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Test cohort 1 - ruxolitinib","EXPERIMENTAL","Days +3 through +4: Bendamustine 50 mg\u002Fm2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg\u002Fkg iv x 2 days; Days -1 through +21: ruxolitinib 10 mg\u002Fkg\u002Fday p.o.; mycophenolate mofetil Days +5 through +35 30 mg\u002Fkg\u002Fday p.o.; Days +5 through +100: Tacrolimus 0.03 mg\u002Fkg\u002Fday with further correction by concentration",[13],"Drug: Ruxolitinib",{"label":15,"type":10,"description":11,"interventionNames":16},"Test cohort 2 - abatacept",[17],"Drug: Abatacept (Orencia)",{"label":19,"type":10,"description":20,"interventionNames":21},"Experimental: Expansion cohort","Days +3 through +4: Bendamustine 50 mg\u002Fm2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg\u002Fkg iv x 2 days; Days -1,+5, +14, +21 abatacept 10 mg\u002Fkg\u002Fday i.v.; Days +5 through +100: Tacrolimus 0.03 mg\u002Fkg\u002Fday with further correction by concentration",[17],[23,29],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Ruxolitinib","; Days -1 through +21: ruxolitinib 10 mg\u002Fkg\u002Fday p.o.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Abatacept (Orencia)","Days -1,+5, +14, +21 abatacept 10 mg\u002Fkg\u002Fday i.v.",[19,15],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Alexandr D Kulagin, MD, Prof","CONTACT","+78123386265","bmt-director@1spbgmu.ru",{"name":40,"role":36,"phone":41,"phoneExt":28,"email":42},"Ivan S Moiseev, MD, Prof.","+78123386201","moisiv@mail.ru",[44],{"facility":45,"status":46,"city":47,"state":28,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Pavlov University","RECRUITING","Saint Petersburg","197022","Russia","RU",{"type":52,"coordinates":53},"Point",[54,55],30.31413,59.93863,{"lat":55,"lon":54},[58],{"name":28,"role":36,"phone":59,"phoneExt":28,"email":42},"8123387193",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"PRINCIPAL_INVESTIGATOR","Ivan S Moiseev","RM Gorbacheva Research Institute Scientific director","100611294","phase-2-optimization-of-post-transplantation-benadamustine-and-cyclophosphamide-in-patients-with-high-risk-myeloid-malignancies-and-a-partially-mismatched-donor-100611294",false,"NCT07238712","Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy)","APTBCy","Inclusion Criteria:\n\n* Patients with indication for allogeneic hematopoietic stem cell transplantation\n* Patients with \\\u003C10\u002F10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.\n* Peripheral blood stem cells or bone marrow as a graft source\n* Diagnosis:\n\nAcute myeloid leukemia Chronic myeloid leukemia, Ph+ Myelodysplastic Syndromes Myeloprolipherative neoplasms - High-risk disease defined as: Acute myeloid leukemia: \\>5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation Myelodysplastic Syndrome: \\>5% of blasts despite previous therapy Myeloid malignancy with with -7 or complex karyotype, or p53 mutation regardless of blast count in bone marrow Treatment-related myelodysplastic syndrome Second or subsequent allogeneic HCT after relapse of a myeloid malignancy Chronic myelomonocytic leukemia Myeloprolipherative neoplasms, unclassifiable\n\n\\- No severe concurrent illness\n\nExclusion Criteria:\n\n* Patients with indication for allogeneic hematopoietic stem cell transplantation\n* Patients with \\\u003C10\u002F10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.\n* Peripheral blood stem cells or bone marrow as a graft source\n* Diagnosis:\n\nAcute myeloid leukemia Chronic myeloid leukemia, Ph+ Myelodysplastic Syndromes Myeloprolipherative neoplasms - High-risk disease defined as: Acute myeloid leukemia: \\>5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation Myelodysplastic Syndrome: \\>5% of blasts despite previous therapy Myeloid malignancy with with -7 or complex karyotype, or p53 mutation regardless of blast count in bone marrow Treatment-related myelodysplastic syndrome Second or subsequent allogeneic HCT after relapse of a myeloid malignancy Chronic myelomonocytic leukemia Myeloprolipherative neoplasms, unclassifiable\n\n\\- No severe concurrent illness","ALL","18 Years","70 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD",[83,84,85,86,87],"Acute Myeloid Leukemia (AML)","Chronic Myeloid Leukemia","Myelodysplastic Syndromes (MDS)","Myeloprolipherative Neoplsm","Atypical Chronic Myeloid Leukemia",[89,90,91,92,93],"Post-transplantation cyclophosphamide","Post-transplantation bendamustine","graft-versus-host disease","abatacept","ruxolitinib","2025-11-16",{"date":96,"type":97},"2025-11-20","ACTUAL",{"date":99,"type":97},"2025-05-10",{"date":101,"type":77},"2026-12-10",{"name":5,"class":6},1]